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Background: Neovascular glaucoma (NVG) is rare, comprising only 3.9% of all glaucoma cases. The most common
cause of NVG is ischaemic central retinal vein occlusion (iCRVO). NVG frequently results in blindness and painful
end-stage glaucomatous damage leading to the need for enucleation. Currently, there is no preventive therapy for
NVG following iCRVO. Rescue treatments have severe drawbacks. Accordingly, there is a great need for preventing
the often visually devastating outcomes of NVG. The STRONG study is designed to test whether the topically active
anti-angiogenic agent aganirsen is able to inhibit the formation of neovascularisation leading to the development
of secondary NVG in eyes with iCRVO. At the same time, STRONG will provide important information on the natural
course of iCRVO and NVG in a large and well-characterised cohort of such patients.
Methods/design: This protocol describes a phase II/III, prospective, randomised, placebo-controlled, double-masked,
three-armed multicentre study for the investigation of aganirsen, a new topical treatment for iCRVO in order to prevent
NVG. The study will evaluate the efficacy of two different doses of this newly developed antisense oligonucleotide
formulated in an eye emulsion to avoid new vessel formation by blocking insulin receptor substrate-1 (IRS)-1.
This leads to subsequent down-regulation of both angiogenic as well as proinflammatory growth factors such
as vascular endothelial growth factor (VEGF) and tumour necrosis factor (TNF). Eligible patients (n = 333) will
be treated with topical aganirsen or placebo for a period of 24 weeks. They will also be invited to participate in
substudies involving analysis of gonioscopic images, detection of biomarkers for NVG and risk factors for iCRVO.
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Discussion: The STRONG study has the potential to offer a new treatment modality for patients suffering from iCRVO
with a high risk of developing NVG. The topical administration can reduce patients’ burden and risk related to rescue
treatment, such as destructive laser treatment or enucleation, but requires a high level of patient compliance.
Trial registration: EudraCT: 2014-000239-18; ClinicalTrials.gov, ID: NCT02947867. (Registered on 15 October 2016); see
also http://strong-nvg.com.
Keywords: Neovascular glaucoma, Neovascularisation, Ischaemic central retinal vein occlusion, Intraocular pressure,
Aganirsen, Placebo, Topical treatment, Orphan diseaseBackground
Glaucoma is a group of conditions characterised by pro-
gressive optic nerve degeneration and loss of visual func-
tion, ultimately resulting in blindness. In contrast to very
frequent types of glaucoma, secondary neovascular glau-
coma (NVG) is rare at approximately 3.9% of all glau-
coma cases. NVG is very aggressive, the prognosis is
poor, and early, aggressive treatment is required to pre-
vent blindness and painful end-stage glaucoma with
irreversible loss of the eye. One common cause of NVG
is ischaemic central retinal vein occlusion (iCRVO)
[1–4]. iCRVO is a retinal pathology resulting in hypoxia,
which leads to the expression of insulin receptor
substrate-1 (IRS-1). IRS-1 in turn increases VEGF ex-
pression further along in the cascade [5] resulting in the
pathogenic development of new vessels in the anterior
and/or posterior segment of the eye. This new vessel for-
mation can build an irreversible fibrovascular membrane
over the trabecular meshwork and iris, leading to an ob-
struction of the trabecular meshwork and a clinically
relevant increase in intraocular pressure (IOP) [4].
The study drug aganirsen is a 25-mer phosphorothioate
antisense oligonucleotide of 8035 Da that inhibits new
vessel formation by blocking IRS-1 and thus VEGF and
tumour necrosis factor-alpha (TNF-alpha) [6, 7]. Aganir-
sen eye drops (saline solution) are safe at the maximum
dose tested of 430 μg/day, which is equivalent to 10-fold
and 5-fold the doses planned by the proposed study.
Aganirsen eye drops have previously been shown in both
phase II and III clinical trials to significantly inhibit cor-
neal neovascularisation and to be well tolerated [8, 9].
Because the STRONG study planned by this consortium
will be undertaken with a novel galenic formulation
(emulsion) instead of saline eye drops, a comparative
safety bridge study was performed for the two formula-
tions (eye drops for corneal neovascularisation, and emul-
sion for prevention of NVG). No safety concerns occurred
during the study.
Currently, reduction of IOP remains the focus of all
therapeutic approaches for the majority of glaucoma
patients, including those with NVG. For NVG, however,
IOP-lowering medications are moderately helpful be-
cause outflow is obstructed and the accompanyinginflammation and proliferative stimulus lead to the very
poor success rate of fistulating glaucoma surgery.
Currently, the common therapy for neovascularisation is
pan-retinal photocoagulation (PRP), although additional
anti-VEGF intravitreal injections have become more and
more common for the therapy of neovascularisation.
Thermic laser coagulation of the retina by PRP is strongly
advocated and practiced widely for the management of
iCRVO if new vessels have already formed [10, 11].
However, no definite guidelines exist regarding the exact
indication and timing of PRP. As an alternative method of
selective retinal ablation, pan-retinal cryotherapy may be
performed on the peripheral fundus if the ocular media
are too hazy for laser application.
There is a clear need to widen the existing therapeutic
options for the treatment of iCRVO to prevent neovas-
cularisation and NVG, with a specific focus on noninva-
sive therapeutic options aimed at prevention or early
management respectively of the neovascular component
of iCRVO. Hence, it is expected that aganirsen will
benefit patients with iCRVO by interfering at an early
stage in the neovascularisation process. Understanding
the natural course of NVG, including biomarker and risk
factor analysis, will further support the evaluation of
new diagnostic and therapeutic interventions. These re-
sults could help to make early NVG diagnosis independ-
ently of an increased IOP by analysis of body fluids.
The primary objective of this multicentre randomised
controlled study is to assess the efficacy and safety of
aganirsen relative to placebo in preventing NVG in pa-
tients with iCRVO. We will evaluate the appearance of
neovascularisation and the rise in IOP after 24 weeks
(co-primary endpoint). We hypothesise that each of the
two tested aganirsen doses will be superior to the pla-
cebo in preventing NVG at week 24. This study will also
evaluate the effective dose of aganirsen.
The secondary objectives are to evaluate the efficacy of
two aganirsen doses, to assess the aganirsen efficacy
relative to placebo on time to, and intensity of, add-
itional interventions, such as PRP or cryotherapy, to
compare the effect of aganirsen and placebo on health
outcome and quality of life (QoL) and to confirm a posi-
tive safety profile of aganirsen.
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objective quantification of neovascularisation in the anter-
ior part of the eye. For the biomarker substudy, the aim is
to find possible biomarkers for iCRVO and NVG in tears
and serum. The aim of the risk factor substudy is to iden-
tify potential novel risk factors for iCRVO and to evaluate
if some of those parameters can be useful to differentiate
patients who are at a higher risk of developing NVG.Methods/design
Trial sponsor: Gene Signal SA, Genopole Biopark, Evry
(Paris), France. Coordinating centre: University Medical
Center at Johannes-Gutenberg University Mainz, Germany,
Department of Ophthalmology. The study is funded by the
European Commission 7th Framework Programme (Grant
number 305321). This funding source had no role in the
design of this study and will not have any role during its
execution, analysis, data interpretation and dissemination
of study results. The dissemination of study results is
scheduled in a publication master plan and rights are
organised in a consortium agreement. A Scientific
Advisory Board and a Data Safety Monitoring Board
will oversee the trial.
The STRONG trial is a phase II/III, prospective, 1:1:1
randomised, placebo-controlled, double-masked, three-
armed multicentre trial for the study of the topical treat-
ment of iCRVO to prevent NVG with a newly developed
eye emulsion. It plans to enrol up to 333 patients suffer-
ing from a primary iCRVO or a conversion to iCRVO
for no longer than 4 weeks in approximately 35 clinical
sites in eight countries across Europe (Germany, France,
Italy, Great Britain, Portugal, Spain and Hungary and
Belgium; for a detailed list see www.strong-nvg.com).
Trial staff will be trained and will follow standard oper-
ating procedures for the specific assessments and data
collection. One eye per subject will be enrolled in the
study. The study drug aganirsen will be administered as
a topical emulsion in two different dosages and will be
compared with a placebo group (Fig. 1).
Each patient who has signed the Informed Consent
Form is monitored for a period of 30 weeks (24-week
treatment phase and 6-week safety follow-up) during
which patients will attend nine visits (examination
schedule in Table 1; see also Fig. 2. (Additional file 1). A
computer-based centralised randomisation scheme for
all study sites will employ a 1:1:1 treatment assignment
ratio (main study) using block randomisation with se-
quential numbering for each specific trial site. Subjects,
investigators, site personnel, monitoring staff, data man-
agement and other sponsor personnel, excluding the
Clinical Supplies Unit, will be masked to subjects’ as-
signments. Only in the case of a serious adverse event
(SAE), when the masked information is urgently neededfor the treatment of the subject, will treatment allocation
be revealed.
The two study groups will be treated with aganirsen
‘low-dose’ (43 μg per day) or ‘high-dose’ (86 μg per day).
The control group will receive placebo, as there is no
labelled treatment for iCRVO to prevent NVG. The pla-
cebo is optically identical to the aganirsen emulsion.
Images of the anterior segment and gonioscopic pho-
tos of all patients participating in the STRONG study
will be collected and evaluated for neovascularisation
within the imaging substudy. Tears and serum samples
will be collected during the biomarker substudy from
200 patients to evaluate possible markers for both
iCRVO and NVG. The results will be compared with re-
sults of healthy subjects already available in a German
database. Thirty-three eligible patients will be included
in the risk factor substudy across all participating trial
sites. At UMC Mainz, 33 age- and gender-matched
healthy controls will be recruited. Blood samples will be
collected to analyse laboratory parameters for coagula-
tion and fibrinolysis and genetic factors to identify risk
factors for iCRVO.
Protocol assistance at the European Medicines Agency
(EMA) has taken place to define patients with a high
risk for developing NVG. The inclusion criteria must be
fulfilled at both the screening and baseline visits.Inclusion criteria
 Primary iCRVO or conversion to iCRVO for no
longer than 4 weeks in the study eye
 Best-corrected visual acuity (BCVA) ETDRS letter
score <35 letters (<20/200 Snellen equivalent) in the
study eye
 At least a 10-disc area of retinal capillary obliteration
on fluorescein fundus angiography in the study eye
(central fundus: macular area as defined by the optic
disc and the arcades, an approximate 6000-μm circle
around the fovea) and/or large, confluent retinal
haemorrhages in the study eye
 IOP in the study eye ≤21 mmHg
 Male or female adults ≥18 years
 For men and women of childbearing potential,
willingness to utilise adequate contraception and
not become pregnant (or have their partner
become pregnant) during the full course of the
study. Adequate contraceptive measures include
(oral) hormonal contraceptives (stable use for two
or more cycles prior to screening) and other
prescription pharmaceutical contraceptives,
intrauterine device, bilateral tubal ligation,
vasectomy, condom, or diaphragm plus
contraceptive sponge, foam, or jelly
Fig. 1 STRONG trial design
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visits and complete all study-related procedures. A
written informed consent must be provided before
any study-related procedure can be performed
Additionally, at least four out of six criteria must be
fulfilled:
1. A relative afferent pupillary defect (with a normal
fellow eye)
2. At least ten cotton-wool spots in the study eye
3. Venous tortuosity in the study eye
4. Peripheral visual field defects corresponding to
ischaemia: dense scotomas in areas of capillary
nonperfusion in the study eye. Patient cannot see
the I-2e target and has a defective or absent I-4e
isopter (Goldmann perimeter or semiautomatic
kinetic methods (Humphrey or Octopus visual field
analyser), targets I-2e, I-4e, V-4e)
5. Engorged vessels on the iris and/or chamber angle in
the study eye
6. Detectable anterior chamber flare in the study eyeExclusion criteria
1. Ocular conditions with a worse prognosis in the
fellow eye than in the study eye
2. Primary or secondary glaucoma in the study eye
3. Ocular anti-VEGF treatment:(a)Any anti-VEGF ranibizumab or bevacizumab
treatment in the study eye in the last 45 days
before the screening visit
(b)Any anti-VEGF aflibercept treatment in the study
eye in the last 90 days before the screening visit
(c)Anti-VEGF treatment in the fellow eye during
the trial4. Any prior or concomitant use of systemic anti-
VEGF products
5. Previous use of intraocular corticosteroids in the
study eye at any time or use of periocular
corticosteroids in the study eye within 90 days
prior to the screening visit
6. Previous use of intraocular or periocular corticosteroids
in the fellow eye within 90 days prior to the
screening visit
7. History of idiopathic or autoimmune uveitis in
either eye
8. Presence of anterior segment neovascularisation
(neovascularisation of the angle (NVA) or
neovascularisation of the iris (NVI)), neovascularisation
of the disc (NVD) or neovascularisation elsewhere
(NVE) in the study eye
9. Previous PRP in the study eye
10. Previous cyclocryocoagulation in the study eye
11. Pregnancy and lactation
12. Any abnormality in the study eye preventing reliable
applanation tonometry
13. Intraocular surgery (other than intravitreal anti-
VEGF treatment) or laser treatment in the study
eye within the last 90 days before the screening visit
14. Evidence at examination of infectious blepharitis,
keratitis, scleritis, or conjunctivitis in either eye, or
current treatment for serious systemic infection
15. Any ocular disorders in the study eye that, in the
opinion of the investigator, might confound the
interpretation of the study results or any other
reason that, in the opinion of the investigator,
precludes the subject from participating in this study
16. Inability to obtain fundus photographs or fluorescein
angiograms of sufficient quality to be analysed
17. Allergy to fluorescein
18. History of hypersensitivity to the study drug or to
any drug with a similar chemical structure or to
Table 1 Examination schedule
Protocol activity Screening Baseline Week 4 Week 8 Week 12 Week 16 + 20 Week 24/early
termination
Week 30
(follow-up)
V1 V2 V3 V4 V5 V6 + 7 V8 V9
Informed consent X
Demographic data (age, gender) X
Medical and ophthalmic history X
Concomitant medications and
procedures
X X X X X X X X
Adverse events X X X X X X X X
NEI-VFQ-25/EQ-5D/ Compliance
questionnaires
X X X
Vital signs (blood pressure/pulse) X X X
Electrocardiogram X X
Haematology X X X
Blood chemistry X X X
Urinalysis X X X
Obtain blood sample for risk factor
substudy
X
Obtain blood sample for biomarker
substudy
X X X
Pregnancy test (urine or serum)a X
Physical exam X
Best-corrected visual acuity (BCVA)
(ETDRS)
X X X X X X X X
RAPD X
Slit lamp biomicroscopy X X X X X X X X
Goldmann perimetry/semi-automatic
kinetic perimetry
Xd
Schirmer test II (biomarker substudy) X X X
Goldmann applanation tonometry (±1 h) Xc X X X X X X Xc
Gonioscopy (study eye only) X X X X X X X X
Anterior segment and gonioscopic
photographyb
X X X X
Posterior segment OCT (SD-OCT) X X X X X X
Indirect ophthalmoscopy X X X X X X X X
Fundus photographyb X X X
Fluorescein angiographyb X X X
Review inclusion/exclusion criteria X X
Randomisation X
Administer study treatment
(aganirsen or placebo)
X
Drug dispensing/return and bottle weight X X X X X X
Patient diary dispensing/return X X X X X X
Assess rescue treatment criteria X X X X X X
BCVA best-corrected visual acuity, EDTRS Early Treatment Diabetic Retinopathy Study, EQ-5D EuroQoL five dimensions questionnaire, IEC, Independent
Ethics Committee, IOP intraocular pressure, NEI-VFQ-25 National Eye Institute Visual Function questionnaire 25, RAPD relative afferent pupillary defect,
SD-OCT spectral domain optical coherence tomography
aPregnancy tests may also be repeated as per request of IECs or if required by local regulations. Only applicable for women of childbearing potential
bOptional at all other visits: only if neovascularisation is suspected in slit lamp examination, gonioscopy or indirect ophthalmoscopy
cIOP measurement by Goldmann applanation tonometry can be performed at any time of the day at the screening visit, V9 and at an unscheduled
visit. The time (±1 h) of IOP measurement at the baseline visit is mandatory for all other visits (V3–V8)
dPerimetry can be skipped if eligibility is fulfilled by other criteria
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STUDY PERIOD
Enrolment Allocation Post-allocation Follow-up
TIMEPOINT** V1 V2
V3 
(week 
4)
V4 
(week 
8)
V5 
(week 
12)
V6+
7
(week 
16+20)
V8 (week 24 / 
early 
termination)
V9 (week 30)
ENROLMENT:
Eligibility screen X X
Informed consent X
Demographic data X
Medical and 
ophthalmic history
X
Concomitant 
medications and 
procedures
X X X X X X X X
Pregnancy test 
(urine or serum)a
X
Allocation / 
Randomization
X
INTERVENTIONS*:
Aganirsen “low-
dose” 43µg daily 
eye drops
X X X X X X (last day)
Aganirsen “high-
dose” 86µg daily 
eye drops
X X X X X X (last day)
Placebo X X X X X X (last day)
ASSESSMENTS:
Vital signs X X X
Electrocardiogram X X X
Haematology X X X
Blood Chemistry X X X
Urinalysis X X X
Physical Exam X
RAPD X
Best-corrected 
visual acuity
X X X X X X X X
Slit lamp 
biomicroscopy
X X X X X X X X
Perimetry Xd
Schirmer test II X X X
Goldmann 
applanation 
tonometryc
X
C
X X X X X X XC
Gonioscopy (study 
eye only)
X X X X X X X X
Anterior segment 
and gonioscopic 
photographyb
X X X X
Posterior Segment 
OCT
X X X X X X
Indirect 
Ophthalmoscopy
X X X X X X X X
Fundus
photographyb
X X X
Fluorescein 
angiographyb
X X X
Adverse Events X X X X X X X X
VFQ 25 / EQ-5D / 
Compliance 
questionnaire
X X X
Patient diary X X X X X X X (last day)
Asses rescue 
treatment criteria
Obtain blood 
samples for risk 
factor sub-study
X
Obtain blood 
samples for 
biomarker sub-study
X X X
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure
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the investigational medicinal products
19. History of other disease, metabolic dysfunction,
physical examination finding, or clinical laboratory
finding giving reasonable suspicion of a disease or
condition that, in the opinion of the investigator,
contraindicates the use of an investigational drug,
might affect interpretation of the results of the
study, or renders the subject at high risk from
treatment complications
20. History of breast cancer
21. Medical or psychological condition that would not
permit completion of the trial or signing of an
informed consent
22. Participation in other clinical trials during the
present clinical trial or within the last 4 weeks
For the risk factor substudy, biomarker and imaging
substudy, the same inclusion and exclusion criteria must
be met by the patients.
Additional exclusion criteria were defined for the eligi-
bility of patients for the risk factor substudy: age 65
years or older, renal insufficiency and acute malignant or
inflammatory reaction (systemic or local).
The co-primary efficacy endpoints combine a neovas-
cularisation component: presence of anterior segment
neovascularisation (NVI or NVA), NVD and/or NVE in
the study eye requiring PRP rescue treatment or cryo-
therapy rescue treatment up to week 24 scored dichot-
omously (yes/no) and an IOP component: percentage
change (≥20%) in IOP compared to baseline and >21
mmHg in the study eye scored ‘failure’, while otherwise
‘success’.
The secondary endpoints of the trial are the time of
development of secondary NVG in the study eye up to
week 24 (in case aganirsen does not totally inhibit but
slows down the development of NVG); the time of de-
velopment of anterior segment neovascularisation (NVI
or NVA); NVD or NVE in the study eye requiring PRP
or cryotherapy up to week 24; the development of
changes in BCVA (ETDRS letter score) in the study eye
up to week 24 (from baseline); the development of
needed additional laser treatments and re-treatments in
the study eye at up to week 24 including the intensity of
the needed additional treatment; the development of
changes in the size of retinal nonperfusion areas in the
study eye up to week 24 in comparison with the base-
line; the development of changes in the National Eye
Institute Visual Function questionnaire 25 (NEI-VFQ-25)
health questionnaire total score at week 24 in comparison
with the baseline; the development of changes in the
EuroQoL five dimensions questionnaire (EQ-5D) health
questionnaire (validated questionnaires) score at week 24
in comparison with baseline; absolute change frombaseline in central retinal thickness in the study eye,
assessed by spectral domain optical coherence tomog-
raphy (SD-OCT) at week 24; NVG classification at 24
weeks on a scale from 1 (non-NVG) to 6 (most advanced
NVG) based on central reading of neovascularisation and
incidence, causality and intensity of adverse events
between the treatment arms.
All randomised subjects, regardless of treatment
group, may receive rescue treatment (e.g. PRP, cryother-
apy or other, as routinely performed at the clinical site)
at any time during the trial if they progress to anterior
segment neovascularisation (NVI or NVA), NVD, or
clinically relevant NVE in the fundus. In this case, the
primary endpoint is reached and the patient will not fur-
ther receive study medication. Should a patient re-
ceive rescue treatment with intravitreal anti-VEGF
(i.e. Lucentis®, Eylea®) because of macular oedema (in-
dividual decision of the investigator), the patient will
not further receive the study drug, but will be followed up
for safety reasons.
The clinical trial will be performed in consideration of
the Declaration of Helsinki and the International Con-
ference on Harmonisation – Good Clinical Practice
(ICH-GCP). The protocol (Version No.:1.4/Date 7 Jan
2015 Final) is approved by the institutional Ethics Com-
mittee from the Landesärztekammer Rheinland-Pfalz,
Germany, and by the French Ethics Committee. Ethics
approval in other participating countries/sites will fol-
low. Any protocol amendment will be approved by the
Ethics Committees and will be distributed to all partici-
pating trial sites via the sponsor’s delegated clinical
research organisation. Additionally, all necessary docu-
ments in the current version will be available on a
password-protected website. Personal information of
participants will be treated as confidential. Only an-
onymous data will be forwarded to the sponsor for
scientific evaluation. Data entry and storage is performed
via an electronic data capture (EDC) system, including
plausibility checks.
Statistics
Presentation of the sample size is based on both aganir-
sen doses combined demonstrating superiority placebo
on the co-primary endpoints of neovascularisation and
IOP at 24 weeks. Calculation of the sample size is based
on the following: (1) An aganirsen to placebo ratio of
2:1, (2) Neovascularisation measured dichotomously
(NVG = yes/NVG = no) with estimated disease rates in
the population of 0.25 for aganirsen and 0.48 for pla-
cebo. Testing of neovascularisation will be done using
the normal approximation to the chi-square distribution
for consistency with O’Brien-Fleming Alpha spending,
which is also computed based on normal approximation,
(3) IOP measured dichotomously with estimated rates of
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for placebo at 24 weeks and (4) Up to four performed
analyses. Based on albeit heterogeneous historical data,
we estimate that 25% of subjects in the aganirsen group
and 48% in the placebo group will develop NVG by 24
weeks. Given a 2:1 aganirsen to placebo assignment
ratio, a total of 300 evaluable subjects – 200 with
aganirsen and 100 with placebo – will provide 80%
power to reject the null hypothesis that aganirsen is
no better than placebo. Power computation is based
on the chi-square test with a two-sided alpha = 0.05.
Assuming that approximately 10% of subjects will not
be evaluable due to loss to follow-up and other
reasons, a total of 333 subjects are planned for this
trial. Missing values of NVG and IOP will be imputed
using the last observation carried forward (LOCF)
method.
Primary efficacy will be assessed up to four times: two
initial futility analyses, followed by an interim analysis for
success/futility/continuation and a final analysis. The data
will be summarised in tables listing the mean, standard
deviation, minimum, median, maximum and number
of subjects in a group for continuous data or in
tables listing count and percentage for categorical
data, where appropriate. Data listing by subject will
be provided. The effects of noncompliance, dropouts
and covariates, and their interactions with treatment
will be assessed to determine the impact on the
general applicability of results from this study. Secondary
comparisons will be considered exploratory, so that there
will be no Type I error adjustment for multiple secondary
comparisons.Co-primary efficacy I: NVG
The primary efficacy analysis will compare the propor-
tion of subjects who developed NVG in the combined
aganirsen arms versus in the placebo group. The analysis
will test the following hypotheses: H0: P(NVG)aganirsen ≥
P(NVG)placebo and H1: P(NVG)aganirsen < P(NVG)placebo,
where P(NVG) is the proportion of subjects developing
NVG by 24 weeks. The hypotheses will be tested using
chi-square normal approximation. (‘Yes’: development of
NVI, NVA, NVD and/or NVE, or rescue treatment and
‘No’: otherwise).Co-primary efficacy II: IOP
H0: Proportion (IOP Failure)aganirsen ≥ Proportion (IOP
Failure)placebo and H1: Proportion (IOP Failure)aganirsen <
Proportion (IOP Failure)placebo, where IOP Failure = in-
crease in IOP from baseline to week 24 by ≥ 20% and
IOP > 21 mmHg, or rescue treatment, and IOP success =
otherwise.Comparison by normal approximation to chi-square test
For both co-primary endpoints: (I) At interim analysis
after data of 240 subjects have accumulated using
two-sided alpha = 0.02442 and (II) If needed, after data
from 300 subjects have accumulated using two-sided
alpha = 0.04288. Interim and final alphas determined by
the O’Brien-Fleming method.
Secondary efficacy analysis
Aganirsen arms combined versus placebo: secondary
analyses will be considered exploratory. Time to devel-
opment of anterior neovascularisation will be compared
by t test or Wilcoxon rank sum test (depending on dis-
tribution), since missing data will be imputed using
LOCF and there will be no censored data.
Continuous change from baseline to week 24 parame-
ters (e.g. size of retinal nonperfusion areas) will be
assessed by analysis of covariance (ANCOVA), the co-
variate being a subject’s baseline variable, to prevent re-
gression towards the mean. If the model shows a lack of
fit, ANCOVA will be conducted on ranked data. The
number of additional laser treatments will be compared
between groups by Poisson regression.
Imaging substudy
Because the imaging analysis is a novel investigation, its
analysis will be iterative and relatively open-ended; the
choice of statistical analyses is likely often to depend on
the results obtained in preceding analyses. Statistical
analysis of the imaging data will be performed in three
parts, all using 24-week data: (1) Development of an ob-
jective scoring technique based on receiver operating
characteristic curve methodology, (2) Assessment of the
relationship between continuous severity scoring of the
disease and imaging parameters and (3) Comparison of
imaging parameters between the aganirsen exposure
arms and placebo. Two thirds of the data of all arms
combined will be used to develop the objective scoring
methodology. This will comprise the ‘learning’ dataset.
One third of the data will not be included in the ini-
tial analysis and will be retained as the ‘validation’
dataset. Objective imaging parameters (e.g. area of iris
covered by neovessels) will be related to NVG diag-
nosis using a stepwise logistic regression. The final
model will retain imaging parameters with P ≤ 0.10,
including interactions. Each subject will receive a
score generated by the final model.
Biomarker substudy
Statistical analysis of the tear and blood data will be per-
formed in three parts: (1) Identifying factors that dis-
criminate between subjects with and without NVG, (2)
Analysing the longitudinal effect of treatment on
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factors that predict a successful outcome of the
treatment.
Because this study is exploratory, different statistical
classification approaches will be used: (a) Logistic regres-
sion, including the process of variable selection and (b)
Data mining tools (e.g. supervised clustering and classifi-
cation trees). To optimise the model parameters, cross-
validation and bootstrap methods will be applied. The
longitudinal effects of aganirsen versus placebo on im-
munological responses of the eye will be examined. Es-
sentially, the patterns of immunological response over
time in the treatment groups will be examined. This lon-
gitudinal effect will be examined by using repeated mea-
sures analysis of variance and regression models.
Risk factor substudy
In this substudy, general laboratory results at baseline
and subject demographics will be related to the develop-
ment of NVG in three groups: (1) Study subjects who
developed NVG, (2) Study subjects who did not develop
NVG and (3) Age-matched controls. Differences in la-
boratory results will be assessed to evaluate the degree
to which laboratory results and baseline factors predict
the development of NVG. Additional analyses will exam-
ine the development of NVG in study subjects by
whether they received active treatment. Analyses for dis-
criminating between groups will include dichotomous
and multinomial logistic regression as needed.
Discussion
The STRONG trial is a phase II/III, prospective, rando-
mised, placebo-controlled, double-masked, three-armed
multicentre trial for the study of the topical treatment of
iCRVO to prevent NVG with a newly developed eye
emulsion. The study has the potential to offer a new,
safe and effective treatment for patients suffering from
iCRVO who have a high risk of developing NVG. NVG
develops as a result of iCRVO typically after an average
period of approximately 90 days but might also appear
as early as 2 weeks or, alternatively, after a much longer
period of time [12]. Early diagnosis of the disease
followed by immediate treatment is critical to avoid a
further development to neovascularisation and NVG.
Early changes of the disease are present, although they
are not visible in many cases [13]. Hypoxia is responsible
for the release of angiogenic factors, including VEGF,
resulting in growth of new vessels in the anterior cham-
ber angle (NVA), iris surface (NVI), the optic disc
(NVD) and elsewhere in the retina (NVE). IRS-1 is
expressed, in particular, in human retinal pathologies,
such as hypoxia, and increases VEGF expression further
along in the cascade [5]. Therefore, IRS-1 has been re-
ported to have an important role in pathologicalangiogenesis and retinal neovascularisation [7, 14]. Aga-
nirsen inhibits the biosynthesis of interleukin-1β and
IRS-1 in pathological angiogenesis by blocking VEGF
messenger ribonucleic acid to restore normal VEGF ex-
pression, thus preventing neovascularisation and NVG
[6, 7].
According to their mechanism of action, anti-VEGF
agents have also been considered in the management of
neovascularisation in iCRVO, but they are used off-label
[15–19] and usually in a late stage when neovascularisa-
tion has already occurred. In addition to the patients’
burden, several ocular drawbacks and side effects such
as IOP elevation, endophthalmitis, retinal detachment or
injury of the lens [20, 21], might be associated with the
invasive and often multiple intravitreal injections. At
present, PRP is the common method used for reducing
retinal ischaemia or neovascularisation in patients with
iCRVO, even though there are major drawbacks of PRP,
such as persistent visual field defects. To target the ret-
ina with aganirsen and avoid the invasive route of intra-
vitreal injections, an emulsion formulation of the active
substance aganirsen was developed by Gene Signal SA
(Genopole Biopark, Evry (Paris), France). Despite ad-
vances in the medical and surgical management of glau-
coma, the visual prognosis for patients with NVG
remains poor [22]. Furthermore, the current thera-
peutic treatment options show many disadvantages in-
cluding peripheral visual field loss after PRP [23],
limitations and discomfort.
The study drug aganirsen is geared toward early treat-
ment of the underlying disease, iCRVO, to avoid the
progression to neovascularisations and further NVG.
Aganirsen was developed as an eye emulsion to reach
the affected areas of the retina and is applied topically. It
is hoped that the topical application of aganirsen eye
emulsion will have fewer side effects compared to the
current standard therapy, which includes laser therapy,
intravitreal injections and/or surgery. It could, therefore,
overcome the disadvantages and limitations of the
current therapeutic options, particularly the surgical
ones, and has the potential to change the current man-
agement of NVG progressing to iCRVO because it may
prevent NVG instead of treating its symptoms. The out-
come of the trial will have potentially significant eco-
nomic impacts considering the high costs for the health
care system due to advanced glaucoma and the risk of
blindness. Furthermore, if successful, it will have a sig-
nificant impact on the patients’ QoL, considering the
painful end stages of NVG, risks of laser therapy, pos-
sible blindness and enucleation, etc. Positive study re-
sults of this EMA-approved study protocol will pave the
way to marketing authorisation in Europe.
The STRONG study, including its substudies, will pro-
vide important data on the natural course of iCRVO and
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stand the natural course of the disease is a semiauto-
matic method for vessel quantification on photographs
[8, 24], which will allow for the evaluation and grading
of the development of NVI and NVA and the quantifica-
tion of iris vessel dilation and the degree of NVI. Fur-
thermore, proteomics and immunoproteomics of
biomarkers in the blood and tear fluid have been shown
to be useful in improving the diagnostics and prognosis of
different ophthalmologic diseases and understanding their
pathogenesis [25–32]. Prognostic parameters for treat-
ment effects could also be established [27, 33–38]. In
addition to the well-known classical risk factors, new
haemostasis-related ones have been investigated in pa-
tients affected by CRVO [39]. There is one study suggest-
ing that high levels of soluble endothelial protein C
receptor (sEPCR) might be a risk factor for retinal vein oc-
clusion (RVO) because the levels were higher in patients
with CRVO than in those with branch retinal vein occlu-
sion (BRVO) and controls [40]. Together with the bio-
marker analysis and the identification of patients at a high
risk for the development of NVG after iCRVO, there
could be a great potential for the early diagnosis of pa-
tients who will convert to NVG after iCRVO, which would
allow for an intervention before the progression to neo-
vascularisation to avoid progression to NVG.
The pool of patients evaluated by the STRONG con-
sortium is small for several reasons. First, iCRVO is a
rare disease (EMA Orphan Drug Designation EMA/
COMP/256922/2014). The prevalence of CRVO is be-
tween 2.8/10,000 and 4.2/10,000 [41]. The ischaemic
form of CRVO represents 20% [42] to 33% [11], which
results in a prevalence of approximately 1/10,000 for
people aged 30 years or older (well below the EMA’s or-
phan ceiling of 5/10,000). Additionally, the inclusion and
exclusion criteria are very strict but are in line with the
EMA Protocol Assistance. The criteria will ensure the
identification of patients with iCRVO with a very high
risk of developing NVG [2, 10, 43, 44]. However, pa-
tients with iCRVO not only have a high risk for the de-
velopment of NVG, but they also frequently suffer from
macular oedema, which is now frequently treated with
anti-VEGF agents, such as off-label bevacizumab, or with
ranibizumab (Lucentis®) or aflibercept (Eylea®) after mar-
keting authorisation for the treatment of macular
oedema after CRVO [22, 45]. The treatment regimen for
macular oedema following CRVO has changed in the
last few years, and macular oedema is now often treated
at a very early stage. Therefore, patient recruitment is
becoming increasingly difficult. Patients with previous
anti-VEGF therapy (45 or 90 days before screening, de-
pending therapy type) are excluded from this trial. How-
ever, ethical concerns for patients can be excluded
because rescue treatment with anti-VEGF for macularoedema is allowed at any time if deemed necessary (indi-
vidual decision of the investigator). Following the guide-
lines of the German Ophthalmological Society, for
patients with a visual acuity <0.05, an injection should
only be administered if there remains, due to the mor-
phological findings, a legitimate prospect of a visual im-
provement by the therapy to more than 0.05 [46]. Only
patients with a very bad visual acuity (<0.1) with a poor
prognosis will be enrolled. In addition, there is
the possibility of improvement of the macular oedema
(delaying or avoiding the necessity of an anti-VEGF
treatment) by aganirsen treatment in two thirds of all
patients. PRP, and also cryotherapy, is strongly advocated
and practiced widely for the management of iCRVO if
neovessels have already formed [10, 11]. The lack of
regulatory-approved preventive therapies for NVG ne-
cessitates the comparison to a placebo. The treatment of
NVG with anti-VEGF is off-label [44]. If rescue treatment
for macular oedema is necessary, the patient will not con-
tinue to receive the study drug but will be followed up for
safety. The trial patients will not incur any disadvantages
in participating in the trial, even if they are allocated to
the placebo arm because currently, there is no therapy
available to prevent NVG resulting from iCRVO. The
close visit scheme will further help to detect progression
of the disease and to intervene quickly.
ICRVO and NVG are both rare diseases [2, 11, 41, 42].
Aganirsen received Orphan Medicinal Product status for
the treatment of NVG in 2003 (EU/3/03/161) and Orphan
Drug status for the treatment of CRVO in 2014 (EMA/
COMP/164746/2014; EMA/OD/008/14). The recruitment
period is quite short for a rare disease, which will
also make it difficult to reach the recruitment target.
To overcome this challenge, a project partner, AIBILI,
the coordinator of the EVICR.net, is in close contact
with all of the member sites across several European
countries to ensure fast evaluation of potential trial
sites and recruitment of patients.
The fact that aganirsen will be applied topically by the pa-
tients themselves could influence the results and outcomes
of the study. Glaucoma therapy with topical medications
requires good patient compliance to achieve optimal thera-
peutic results. A consistent and correct application of the
drug is difficult, especially for older patients. Patients might
forget to apply the medication or they might not be aware
of its importance due to the asymptomatic course of the
disease [47–49]. Studies have shown a rate of noncom-
pliance in glaucoma patients of approximately 25-50%.
Compliance is also strictly required for the STRONG
trial. Therefore, several methods will be applied to in-
crease and control patient compliance, such as drug ac-
countability after drug return and evaluation of patient
diaries. The patient advocacy group Bundesverband
Glaukom-Selbsthilfe e.V., a consortium member,
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ing this chronic disease and the correct eye drop appli-
cation to overcome this matter.
The STRONG trial has to overcome several difficul-
ties, but if successful, offers many therapeutic chances
and opportunities for patients with this rare disease.
Trial status
The study is in preparation. It is not yet open for partici-
pant recruitment.
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